Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Loading live signals…
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Executive ChangeItem 5.02 · 8-KLOW RiskPositive
BioCryst Pharmaceuticals, Inc.
Filed: Jun 11, 2026CIK: 0000882796
AI Executive Summary
AI-powered analysis of 8-K filing content
BioCryst Pharmaceuticals stockholders approved an amendment to the Stock Incentive Plan on June 11, 2026, increasing available shares by 7,000,000 to enhance employee compensation and retention strategies.
Key Takeaways
7,000,000 additional shares authorized for issuance under the Stock Incentive Plan
Amendment approved by majority vote at the Annual Meeting of Stockholders
2 more takeaways
Filing Overview
Form Type8-K
Filing DateJun 11, 2026
Item5.02
CategoryExecutive Change
CIK0000882796
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
stock offering
What This Means
A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.